tbuckley/cabot-search huggingface dataset:
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Authors: Gina A. Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey, Helmut Wittkowski, Philip J. Hashkes, Yackov Berkun, Susanne Schalm, Sara Murias, Jason A. Dare, Diane Brown, Deborah L. Stone, Ling Gao, Thomas Klausmeier, Dirk Foell, Adriana A. de Jesus, Dawn C. Chapelle, Hanna Kim, Samantha Dill, Robert A. Colbert, Laura Failla, Bahar Kost, Michelle O’Brien, James C. Reynolds, Les R. Folio, Katherine R. Calvo, Scott M. Paul, Nargues Weir, Alessandra Brofferio, Ariane Soldatos, Angelique Biancotto, Edward W. Cowen, John J. Digiovanna, Massimo Gadina, Andrew J. Lipton, Colleen Hadigan, Steven M. Holland, Joseph Fontana, Ahmad S. Alawad, Rebecca J. Brown, Kristina I. Rother, Theo Heller, Kristina M. Brooks, Parag Kumar, Stephen R. Brooks, Meryl Waldman, Harsharan K. Singh, Volker Nickeleit, Maria Silk, Apurva Prakash, Jonathan M. Janes, Seza Ozen, Paul G. Wakim, Paul A. Brogan, William L. Macias, Raphaela Goldbach-Mansky
Journal: Journal of Clinical Investigation (2018)

BACKGROUND. Monogenic IFN–mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease.
Genomic evolution and acquired resistance to preoperative chemoradiation therapy (CRT) in rectal cancer.
Authors: Sophia C. Kamran, Jochen K Lennerz, Claire Margolis, David Liu, Brendan Reardon, Stephanie A Wankowicz, Jennifer Yon-Li Wo, Henning Willers, Ryan Bruce Corcoran, Eliezer Mendel Van Allen, Theodore S. Hong
Journal: Journal of Clinical Oncology (2018)

613 Background: Following pre-operative CRT for locally advanced rectal cancer, ~20% of patients achieve a pathologic complete response and 20-40% have little to no response (NR) at time of surgery. Pathologic downstaging after CRT is associated with improved outcomes but molecular predictors of response are poorly understood. The objective of this study was to characterize somatic mutations and derive genomic biomarkers distinguishing complete and excellent partial responders (R) vs NR through whole exome sequencing (WES) in pre- and post-CRT tumor samples. Methods: Rectal cancer patients treated with pre-operative CRT and having either a R or NR were identified. DNA extraction from clinical FFPE samples and WES were performed on pre/post-CRT tumor and matched germline DNA followed by genomic analysis to identify somatic mutations, insertion/deletions, and clonal/subclonal mutational evolution. RNA extraction/sequencing and GSEA was performed in parallel. Results: We identified 34 pre- and post-CRT matched tumor samples from 17 patients treated with pre-operative fluoropyrimidine-based CRT (50.4 Gy) followed by surgery within 8-10 weeks. Nine and 8 patients were classified as NR and R, respectively. All FFPE passed quality control metrics and were successfully sequenced. Mean somatic mutational burden pre-CRT was 3.78 mutations/Mb (rg, 2.25-8.43), which, unexpectedly, was not significantly increased in the post-CRT samples (4.23 mutations/Mb; rg, 1.74-8.96). NR cases had more concurrent KRAS/TP53 (KP) mutations than R cases (67% vs 13%, p &lt; 0.05). Related to this finding, NR was associated with epithelial-to-mesenchymal transition (p &lt; 0.001) and potentially linked to high intra-tumoral heterogeneity pre-CRT (p = 0.08). Conclusions: We have established feasibility and a pipeline for performing WES on pre- and post-CRT FFPE tumor samples. Our data suggest that evolution of CRT resistance is not through hypermutation. In conjunction with recent observations from our group (Hong, JNCI 2017; Wang, Cancer Res 2017), our findings strongly support the clinical utility of the KP genotype as a biomarker of CRT resistance and begin to offer insight into the underlying mechanisms on a genomic level.
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Authors: Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J. Hochmair, Steven F. Powell, Susanna Y.-S. Cheng, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina C. Garassino
Journal: New England Journal of Medicine (2018)

First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 2018;73:890–6.
Authors: Pim J. van Leeuwen, Henk G. van der Poel
Journal: European Urology (2018)
Abstract 12514: Myocardial Glucose Metabolism Evaluated by Fasting 18Fluorodeoxyglucose-Positron Emission Tomography in Pulmonary Hypertension
Authors: Tomohisa Nakamura, Nobuhiro Tahara, Youichi Sugiyama, Munehisa Bekki, Atsuko Tahara, Akihiro Honda, Eita Kumagai, Sachiyo Igata, Yoshihiro Fukumoto
Journal: Circulation (2016)

Background: The myocardium changes its energy substrate from fatty acid oxidation to glycolysis under increased afterload. 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) can provide clinical information about myocardial glucose metabolism. Purpose: We aimed to investigate the myocardial glucose metabolism in patients with pulmonary hypertension (PH). Methods: We studied 45 patients with pre-capillary PH (36 females; mean age 54 ± 16 years), who underwent magnetic resonance imaging and FDG-PET. FDG uptake in the right ventricle (RV) and left ventricle (LV) was measured by maximum standardized uptake values (SUV). Further, we examined whether pulmonary vasodilators could shift the myocardial glucose metabolism in 30 patients. Results: The ratio of FDG uptake between RV to LV (SUV R/L ) and mean pulmonary arterial pressure (mPAP) were 0.84±0.08 and 39.2±1.7 mmHg, respectively. Multiple stepwise regression analysis revealed that mPAP was independently associated with SUV R/L (R 2 =0.396). The SUV R/L was significantly decreased from 0.88±0.41 to 0.70±0.29 ( p &lt;0.05) by treatment with pulmonary vasodilators. The increases in RV ejection fraction and 6-min walk distance were independently associated with the decrease in SUV R/L after treatment (R 2 =0.466). Conclusions: The present study reveals that SUV R/L is associated with disease severity of PH, suggesting that myocardial glucose metabolism may contribute to its clinical importance of patient care.
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease
Authors: Herbert Decaluwé, Christophe Dooms, Paul De Leyn, Pascal Thomas, Ramon Rami-Porta
Journal: European Respiratory Journal (2018)

We would like to thank A. Addeo and G. Banna for their correspondence with comments on our article entitled "Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study" [1]. In this prospective multicentre study, we found a 25% rate of unforeseen N2 disease after staging and resection, confirming the result of a previous prospective study, similar in size and design, investigating the performance of endosonography in the mediastinal staging of clinical N1 (cN1) patients [2]. However, the sensitivity and negative predictive value of videomediastinoscopy versus endosonography was 0.73 (95% CI 0.54–0.86) versus 0.38 (95% CI 0.18–0.57) and 0.92 (95% CI 0.83–0.97) versus 0.81 (95% CI 0.71–0.91), respectively. We acknowledge the lower accrual than initially projected, which resulted in wider width of confidence interval than aimed for. Nonetheless, with these results we argue that videomediastinoscopy could be the preferred technique of invasive mediastinal staging in patients with cN1 disease, outperforming endosonography in this patient group. In patients with clinical N1 NSCLC, videomediastinoscopy outperforms endosonography as a mediastinal staging tool <http://ow.ly/ShP330iWzN2>
Regionalization, Readmissions, and Repercussions of Major Cancer Surgery
Authors: Srinivas J. Ivatury, Sandra L. Wong
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial
Authors: Saptharishi Lalgudi Ganesan, Muralidharan Jayashree, Sunit Chandra Singhi, Arun Bansal
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Although case series describe benefits of airway pressure release ventilation (APRV), this mode of ventilation has not been evaluated against the conventional low-tidal volume ventilation (LoTV) in children with acute respiratory distress syndrome (ARDS).To compare the effect of APRV and conventional LoTV on ventilator-free days in children with ARDS.This open-label, parallel-design randomized controlled trial was conducted in a 15-bed ICU. Children aged 1 month to 12 years satisfying the modified Berlin definition were included. We excluded children with air leaks, increased intracranial pressure, poor spontaneous breathing efforts, chronic lung disease, and beyond 24 hours of ARDS diagnosis or 72 hours of ventilation. Children were randomized using unstratified, variable-sized block technique. A priori interim analysis was planned at 50% enrollment. All enrolled children were followed up until 180 days after enrollment or death, whichever was earlier.The trial was terminated after 50% enrollment (52 children) when analysis revealed higher mortality in the intervention arm. Ventilator-free days were statistically similar in both arms (P = 0.23). The 28-day all-cause mortality was 53.8% in APRV as compared with 26.9% among control subjects (risk ratio, 2.0; 95% confidence interval, 0.97-4.1; Fisher exact P = 0.089). The multivariate-adjusted risk ratio of death for APRV compared with LoTV was 2.02 (95% confidence interval, 0.99-4.12; P = 0.05). Higher mean airway pressures, greater spontaneous breathing, and early improvement in oxygenation were seen in the intervention arm.APRV, as a primary ventilation strategy in children with ARDS, was associated with a trend toward higher mortality compared with the conventional LoTV. Limitations should be considered while interpreting these results. Clinical trial registered with www.clinicaltrials.gov (NCT02167698) and Clinical Trials Registry of India (CTRI/2014/06/004677).
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.
Authors: Guillem Argiles, Takayuki Yoshino, Atsushi Ohtsu, Robert J. Mayer, Robert Winkler, Nadia Amellal, Ronan Fougeray, Akira Kanehisa, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2018)

744 Background: Elevated neutrophil-to-lymphocyte (NLR) ratios may represent markers of a suboptimal host immune response to cancer and have been shown to correlate with prognosis in multiple tumor types. Trifluridine/tipiracil (FTD/TPI also known as TAS-102) compared with placebo significantly improved OS (median: 7.1 vs.5.3 months, hazard ratio (HR) = 0.68, 95% confidence interval (CI) [0.58;0.81], p &lt; 0.0001), PFS, and DCR in the phase 3 RECOURSE study, conducted in patients with refractory mCRC. A post-hoc analysis was conducted to assess correlation between clinical outcomes and baseline NLR (in blood) in RECOURSE. Methods: A retrospective review on 782/800 patients, with available NLR, was performed on OS, PFS, and DCR in two subgroups of patients with low ( &lt; 3) or high (≥ 3) NLR at baseline. Based on literature, the cutoff value of 3 was chosen as the number of patients was similar in each NLR subgroup. Between-group comparison was performed using a stratified Cox’s proportional hazard model for OS and PFS, and Fisher’s Exact test for DCR. Results: The median value of NLR at baseline was similar in each group, FTD/TPI (N = 519): 4.4 ± 6.3, placebo (N = 263): 4.7 ± 6.5. Almost 60% of patients in each group had high NLR. In the low NLR vs. high NLR subgroup, there were differences at baseline for ethnic origin (Asian: 45% vs.29%), ECOG PS 0 (69% vs. 49%), and number of metastatic sites ≥ 3 (32% vs. 46%). The median OS [95 % CI] was statistically significantly higher in the low vs. high NLR subgroup: 8.4 [7.8;9.5] vs. 5.3 [4.7;5.7] months, HR = 0.49, 95% CI [0.41;0.59], p &lt; 0.0001. Irrespective of NLR, all patients benefited from FTD/TPI vs. placebo. The results of PFS and DCR were statistically significantly better in the low NLR vs. high NLR subgroup. The multivariate Cox analysis for OS with the interaction test between treatment groups and NLR showed that NLR is not a predictive factor (p = 0.15). Conclusions: In this retrospectively analyzed mCRC population, NLR was shown to be an independent prognostic factor. Further research is warranted to assess if NLR can be a stratification factor in mCRC clinical trials. Clinical trial information: NCT01607957.
The emerging roles of exosomes in the modulation of immune responses in cancer
Authors: Paul Kurywchak, Jena Tavormina, Raghu Kalluri
Journal: Genome Medicine (2018)

Exosomes are promising tools for improving cancer care, but conversely may also contribute to tumor progression. Here, we highlight recently discovered roles of exosomes in modulating immune responses in cancer, with emphasis on exosomal surface proteins and on RNA and DNA content. We also discuss how exosomes could be exploited as biomarkers and delivery vehicles in cancer therapy.
58P Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)
Authors: C. Codony-Servat, M. Llanos Gil Moreno, J. Bracht, I. Attili, C. Lazzari, V. Gregorc, M. Ito, S. Viteri, N. Karachaliou, R. Rosell
Journal: Journal of Thoracic Oncology (2018)
Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock
Authors: Mary E. Keebler, Elias V. Haddad, Chun W. Choi, Stuart McGrane, Sandip Zalawadiya, Kelly H. Schlendorf, D. Marshall Brinkley, Matthew R. Danter, Mark Wigger, Jonathan N. Menachem, Ashish Shah, JoAnn Lindenfeld
Journal: JACC Heart Failure (2018)
The prognostic impact of CD3, CD8, FoxP3, and IL17 tumor-infiltrating immune cells in periampullary cancer differs by morphological type and adjuvant chemotherapy.
Authors: Carl Fredrik Warfvinge, Sebastian Lundgren, Jacob Elebro, Margareta Heby, Agnieszka Krzyzanowska, Anders Bjartell, Bjorn Nodin, Jakob Eberhard, Karin Leandersson, Karin Jirstrom
Journal: Journal of Clinical Oncology (2017)

53 Background: The prognostic impact of tumor-infiltrating T lymphocytes has been evaluated in periampullary carcinoma, but previous studies have not taken into consideration the different morphological subtypes of cancers derived from the periampullary region. Herein, we investigated the prognostic impact and distribution of tumor-infiltrating CD3 + , CD8 + , FoxP3 + T lymphocytes as well as IL-17 + cells in periampullary adenocarcinoma, with particular reference to morpohological subtyoe. Methods: Counts of CD3 + , CD8 + , FoxP3 + T lymphocytes, and IL-17 + cells were assessed using immunohistochemistry on tissue microarrays with tumors from a consecutive retrospective cohort of 175 patients with resected periampullary adenocarcinoma; 110 of pancreatobiliary type (PB-type) and 65 of I intestinal type (I-type). Results: Distribution of all evaluated immune cells differed significantly between PB- and I-type tumors. In I-type tumors, the ratios of IL-17 + /FoxP3 + and IL-17 + /CD3 + were independent factors of poor prognosis. Notably, the unfavorable prognostic impact of IL-17 + was only evident in cases that had not received adjuvant chemotherapy. In PB-type tumors, CD3 + was an independent marker of good prognosis. Conclusions: The results from this study highlight that the composition and prognostic importance of various subsets of infiltrating immune cells in periampullary adenocarcinoma differ by morphological subtype, and potentially by adjuvant chemotherapy.
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells
Authors: C. Bryce Johnson, Bennett R. May, Brian P. Riesenberg, Samantha Suriano, Shikhar Mehrotra, Elizabeth Garrett-Mayer, Mohamed L. Salem, Emily K. Jeng, Hing C. Wong, Chrystal M. Paulos, John M. Wrangle, David J. Cole, Mark P. Rubinstein
Journal: Cancer Research (2018)

Effector CD8+ T cells conditioned with IL12 during activation mediate enhanced antitumor efficacy after adoptive transfer into lymphodepleted hosts; this is due in part to improved IL7 responsiveness. Therefore, we hypothesized that increasing the intensity or type of lymphodepletion would deplete more IL7-consuming host cells and improve the persistence and antitumor activity of IL12-conditioned CD8+ T cells. Using cyclophosphamide, fludarabine, and total body irradiation (TBI, 6 Gy) either individually or in combination, we found that combined lymphodepletion best enhanced T-cell engraftment in mice. This improvement was strongly related to the extent of leukopenia, as posttransfer levels of donor T cells inversely correlated to host cell counts after lymphodepletion. Despite the improvement in engraftment seen with combination lymphodepletion, dual-agent lymphodepletion did not augment the antitumor efficacy of donor T cells compared with TBI alone. Similarly, IL7 supplementation after TBI and transfer of tumor-reactive T cells failed to improve persistence or antitumor immunity. However, IL15 or IL2 supplementation greatly augmented the persistence and antitumor efficacy of donor tumor-reactive T cells. Our results indicate that the amount of host IL7 induced after single agent lymphodepletion is sufficient to potentiate the expansion and antitumor activity of donor T cells, and that the efficacy of future regimens may be improved by providing posttransfer support with IL2 or IL15.Significance: The relationship between lymphodepletion and cytokine support plays a critical role in determining donor T-cell engraftment and antitumor efficacy. Cancer Res; 78(11); 3067-74. ©2018 AACR.
A Target to Achieve Zero Preventable Trauma Deaths Through Quality Improvement
Authors: Zain G. Hashmi, Elliott R. Haut, David T. Efron, Ali Salim, Edward E. Cornwell, Adil H. Haider
Journal: JAMA Surgery (2018)

This study uses the Healthcare Cost and Utilization Project Nationwide Emergency Department Sample to examine the number of preventable trauma deaths in US hospitals to provide a target for the National Academies of Sciences, Engineering, and Medicine mandate of zero preventable deaths after injury.
66P PALB2 mRNA expression as a predictive marker in advanced non-small cell lung cancer (NSCLC) patients (p) treated with docetaxel-cisplatin
Authors: N. Karachaliou, J. Berenguer, I. Chaib, J.L. Ramírez Serrano, M.T. Moran Bueno, B. Massuti Sureda, S. Calabuig Fariñas, C. Camps, M. Provencio Pulla, R. Rosell
Journal: Journal of Thoracic Oncology (2018)
Abstract 15418: Contemporary Use of Ticagrelor in Interventional Practice: Insights From BMC2
Authors: Amrita M Karve, Milan Seth, Manoj Sharma, Hitinder S Gurm
Journal: Circulation (2013)

Background:  Ticagrelor, like prasugrel, has enhanced anti-ischemic efficacy and increased bleeding compared with clopidogrel and has been approved for patients with acute coronary syndromes (ACS). There are no data on the contemporary use of ticagrelor.   Objectives:  To determine use of ticagrelor in clinical practice.   Methods:  We assessed the use of ticagrelor in 43,167 patients who had percutaneous coronary intervention (PCI) and were discharged from October 2011 to December 2012 at 47 Michigan hospitals in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) registry. Pre-procedural risk of major adverse events was estimated with BMC2 risk prediction models using baseline characteristics.   Results:  The proportion of patients receiving clopidogrel, prasugrel, and ticagrelor was 75.7% (n=32,678), 21.7% (n=9,380), and 2.6% (n=1,109) respectively. Ticagrelor was used at 32 hospitals; its use ranged from 0.5% to 15.9 % of total discharges. Compared with patients on prasugrel, those on ticagrelor tended to be female, older, and white (table). A higher proportion of patients on ticagrelor had a history of CABG, presented with STEMI or equivalent, cardiac arrest within 24 hours, and required intra-aortic balloon pump (IABP). Compared with prasugrel, the predicted risk of contrast nephropathy (2.6% vs. 1.6%), transfusion (4.6% vs. 3.5%), and death (1.3% vs. 0.6%) was higher for ticagrelor (p    Conclusion:  Ticagrelor use is low for patients undergoing PCI. Compared to prasugrel, ticagrelor is prescribed to a less stable, higher risk population, and 1 in 5 patients on ticagrelor did not have ACS.
Tumor associated macrophages antagonize antitumor effect of chemotherapy.
Authors: Fei Chen, Shicheng Su, Erwei Song
Journal: Journal of Clinical Oncology (2017)

120 Background: Tumor associated macrophages play an essential role in tumor progression, promoting angiogenesis, immunosupression, invasion and metastasis. However, TAMs regulation of tumor responses to chemotherapy is complicated. In different type of treatment or tumor model, TAMs can either enhance or antagonize antitumor effect of chemotherapy. Methods: We isolated TAMs from breast cancer tissues, or PBMC stimulated with culture medium of mesenchymal breast cancer cells and cocultured with breast cancer cells MCF-7 for 6-10days. After cocultured with TAMs, we treated MCF-7 with docetaxel. In vivo, we use MCF-7 with or without TAMs to generate xenografts in NOD/SCID mice and treated with docetaxel. To testify if the antagonize was dependent on specific treatment, we also treated breast cancer cells with ciaplatin. Results: With coculture of TAMs, we obversed ruduced apoptosis of docetaxel treated breast cancer cells. In mice model, TAMs co-injection xenografts antagonized the antitumor effect of docetaxel.Consisted with previous results, TAMs coculture antagonize the antitumor effect of cisplatin, suggesting the antagonize of TAMs was independent on cell cycle. Conclusions: Collectively, our study indicated the antagonize of TAMs towards chemotherapy.